A View LCS vs cmAngio®
AI Verdict
Choose A View LCS if…
Choose AVIEW LCS if your clinical practice requires a comprehensive AI-powered solution for thoracic CT analysis, including automated lung cancer screening, emphysema quantification, and coronary artery calcification scoring from a single low-dose CT scan. This tool is ideal for facilities seeking to streamline multi-disease detection and reporting within a single imaging workflow.
View A View LCS →Choose cmAngio® if…
Choose cmAngio® if your facility aims to leverage existing mammography exams to assess women's cardiovascular health by detecting Breast Arterial Calcifications (BAC). This AI software provides a non-invasive method to identify BAC without additional radiation, offering valuable insights for early risk assessment in women.
View cmAngio® →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | A View LCS | cmAngio® |
|---|---|---|
| Pricing | Unknown | Paid, out-of-pocket |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker). It can also be integrated into standard reading environments (PACS), RIS (Radiological Information System), or used as a standalone third-party application or web-based application. | Cloud-based, integrates with any DICOM-compliant viewer |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®Tool B explicitly highlights 'Quick and easy installation (less than an hour)' and compatibility with 'any DICOM-compliant viewer,' suggesting a streamlined integration and user experience. While Tool A offers flexible deployment and automated reporting, Tool B's focus on rapid setup and broad viewer compatibility gives it an edge in immediate usability and integration ease.
Clinical Value
A View LCSTool A offers a comprehensive thoracic CT analysis, detecting lung nodules, quantifying emphysema, and scoring coronary artery calcification from a single low-dose CT scan. This multi-faceted diagnostic capability addresses several critical health concerns simultaneously, providing broader clinical utility than Tool B's focused detection of Breast Arterial Calcifications.
Pricing & Value
TieBoth tools require direct contact with the vendor for pricing details, making a direct comparison of their cost-effectiveness impossible. While Tool B mentions potential 'limited-time offers for no-cost implementation and service,' this is not a standard pricing model and does not provide a clear advantage in overall value without more information.
Enterprise Readiness
A View LCSTool A provides superior deployment flexibility, offering cloud-based, hybrid, local dedicated hardware, and locally virtualized options, which is crucial for diverse enterprise IT environments. Additionally, Tool A explicitly states it 'has_baa: 1,' whereas Tool B requires contacting the vendor for BAA details, potentially simplifying the procurement process for Tool A.
Innovation
A View LCSTool A demonstrates significant innovation by performing comprehensive thoracic analysis, including lung cancer screening, emphysema quantification, and coronary artery calcification detection, all from a single low-dose CT scan. Its 'CT kernel conversion AI technology' further highlights advanced technological capabilities. While Tool B innovatively leverages mammograms for cardiovascular risk assessment without additional radiation, Tool A's breadth of analysis from a single scan and its kernel conversion technology represent a broader scope of AI-driven advancement in medical imaging.
Support & Docs
TieNeither the provided structured facts nor readily available public web searches offer specific details regarding the level of support or documentation provided by either vendor. Without this information, it is not possible to distinguish between the two tools in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | A View LCS | cmAngio® |
|---|---|---|
| Name | A View LCS | cmAngiou00ae |
| Company | Coreline Soft Co. | CureMetrix |
| Description | FDA-cleared AI-powered medical imaging platform for comprehensive thoracic CT analysis, specializing in lung cancer screening, emphysema quantification, and coronary artery calcification detection from a single low-dose CT scan. | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. |
| Categories | Cardiology AI, Oncology AI, Radiology & Imaging AI | Cardiology AI, OB/GYN AI, Radiology & Imaging AI |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Obstetrics & Gynecology, Radiology |
| Key Features | Automated lung nodule detection and classification; Nodule volume quantification and measurement (3D); Lung-RADS scoring and reporting; Emphysema analysis and quantification (LAA); Coronary Artery Calcium (CAC) scoring (Agatston, volume, mass); Segmentation of major coronary arteries; Automated comprehensive report generation (PDF, DICOM PDF, SR); CT kernel conversion AI technology | AI-based detection of Breast Arterial Calcifications (BAC); Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams; Provides visualization of BAC location on a scorecard; Enables BAC identification and reporting without additional radiation or procedures; Compatible with any DICOM-compliant viewer; Adjustable operating point to meet clinical goals; Quick and easy installation (less than an hour); Cybersecure and HIPAA-compliant |
Videos
Demos, reviews, and walkthroughs featuring A View LCS and cmAngio®.